Cagrilintide is a long-acting amylin analog being studied in research settings for its receptor activity, pharmacokinetic profile, and potential complementary effects when combined with GLP-1 receptor agonist compounds. Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors in the brain and peripheral tissues.

Receptor Mechanism

Cagrilintide acts on amylin receptors — complexes formed by the calcitonin receptor and receptor activity-modifying proteins (RAMPs). These receptors are expressed in the area postrema, hypothalamus, and brainstem, where amylin signaling is studied for its role in gastric emptying rate, satiety signaling, and glucagon suppression.

Research Context: CagriSema Combination

Cagrilintide has been studied in combination with semaglutide (a combination termed “CagriSema”) for additive or synergistic multi-receptor pathway analysis. Research into amylin/GLP-1 co-agonism examines whether dual-mechanism compounds produce differentiated signaling profiles compared to GLP-1 receptor agonism alone.

Analytical Testing Requirements

As a peptide analog with structural similarity to native amylin, cagrilintide research compounds require mass spectrometry identity confirmation to distinguish the active compound from related sequences. HPLC purity testing alone is insufficient for identity verification in this compound class.

Research use only. Not for human or animal use.